Glioma trials

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors is being studied. Conditions: Neoplasms, Brain, Glioblastoma Multiforme, Glioblastoma of Cerebellum +30 • Eligibility: Inclusion Criteria: * Age ≥ 36 months and \< 22 years * Pathologically proven malignant cerebellar brain tumor (including medulloblastoma, glioblastoma multiforme, giant cell glioblastoma, anaplastic astrocytoma, primitive…. Goal: This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested. Phase/Status/Sponsor: Unknown phase; RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss is being studied. Conditions: Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant +4 • Eligibility: Inclusion Criteria: * Has a tumor with a confirmed MTAP loss * Is ≥18 years of age at the time of signature of the main study ICF *…. Goal: This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumor types with a confirmed MTAP loss. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tango Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma is being studied. Conditions: Astrocytoma, IDH-Mutant, Grade 2, Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant, Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant +4 • Eligibility: Inclusion Criteria: * Patients must have histologically, molecularly, or cytologically confirmed recurrent astrocytic tumors including: * GBM or variants, IDH-wildtype, grade 2-4 (standard curative measures available or not)…. Goal: This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors is being studied. Conditions: Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 +14 • Eligibility: Inclusion Criteria: * Histologically confirmed malignancy that is considered surgically incurable with either: * Stage IIIC melanoma including locally relapsed, satellite, in-transit lesions or bulky draining node metastasis…. Goal: This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors that have spread to other places in the body (metastatic). The study agent is called IL13Ralpha2 CAR T cells. Phase/Status/Sponsor: Unknown phase; RECRUITING; Anusha Kalbasi.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors is being studied. Conditions: Central Nervous System Neoplasms, Atypical Teratoid/Rhabdoid Tumor, Diffuse Midline Glioma, H3 K27M-Mutant +4 • Eligibility: Inclusion Criteria: Screening Eligibility 1. Age ≤ 21 years of age 2. Primary CNS tumor 3. For Cohort A, must have evidence of relapsed or refractory non-brainstem CNS…. Goal: Loc3CAR is a Phase I clinical trial evaluating the use of autologous B7-H3-CAR T cells for participants ≤ 21 years old with primary CNS neoplasms. B7-H3-CAR T cells will be locoregionally administered via a CNS reservoir catheter. Phase/Status/Sponsor: Unknown phase; RECRUITING; St. Jude Children's Research Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma is being studied. Conditions: Glioblastoma Multiforme • Eligibility: Inclusion Criteria To be eligible to participate in the study, a patient must meet all of the following inclusion criteria: * Patient must have radiographically-confirmed progression of, or…. Goal: This multi-site, Phase 1/2a clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with radiographically-confirmed progression of Grade IV glioma or recurrent primary or secondary Grade IV glioma. The study will have two phases, Phase 1 and Phase 2a. Phase/Status/Sponsor: Unknown phase; RECRUITING; Neonc Technologies, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Institutional Registry of Rare Diseases is being studied. Conditions: Rare Diseases, Amyloidosis, Sarcoidosis +23 • Eligibility: Inclusion Criteria: * Clinical and/or molecular diagnosis of any of the following rare diseases: Amyloidosis, Sarcoidosis, Phacomatosis, Pheochromocytoma, Paraganglioma, Von Hippel-Lindau Disease, Immunoglobulin G4-Related Disease, Demyelinating Diseases, Inborn…. Goal: The goal of this observational study is to create a single macro registry system with data collection on common clinical features, grouping the different rare diseases (RD). Moreover, the specific goals are to generate an alert system for possible cases of RD with data from the electronic medical record, to describe the occurrence of RD in the evaluated population, to characterize the population, to describe patterns of diagnosis and treatment of RD present at the time, and to explore patient-reported outcomes. Phase/Status/Sponsor: Unknown phase; RECRUITING; Hospital Italiano de Buenos Aires.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers is being studied. Conditions: Head and Neck Tumors, Kidney Cancers, Small Cell Lung Cancers +3 • Eligibility: * INCLUSION CRITERIA: * Participants must have histopathologically confirmed gastrointestinal neuroendocrine tumors (GI NET), pheochromocytoma/paraganglioma (PPGL), small cell lung cancers (SCLC), kidney cancers (KC), or Head \& Neck…. Goal: Background: Some cancers have high levels of proteins called somatostatin receptors (SSTRs) on the surface of the tumors. These tumors can be in the lung, head and neck, digestive tract, kidneys, and in or near the adrenal glands. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests a combo of AMXT 1501 and DFMO (eflornithine) in children and young adults up to age 21 with relapsed or refractory neuroblastoma, certain brain tumors (including DIPG), and some sarcomas. - The main goals are to find a safe, recommended dose of AMXT 1501 with DFMO, assess safety and tolerability, and learn whether the treatment shows activity by looking at responses and how long the disease stays under control. - The trial includes different age groups (adolescents and young adults 12 and older, and younger children under 12) with age-specific dose considerations. - Key exclusions include body surface area under 0.25 m2, current use of other investigational or anticancer drugs, active infection, or risk factors that would make safety monitoring unreliable.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Targeted Pediatric High-Grade Glioma Therapy is being studied. Conditions: High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma +6 • Eligibility: Inclusion Criteria: 1. Age: Patients must be ≥12 months and ≤39 years of age at the time of enrollment onto this screening protocol. 2. Diagnosis: Patients with newly…. Goal: The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma. This molecular profiling will decide if patients are eligible to participate in a subsequent treatment-based clinical trial based on the genetic alterations identified in their tumor. Phase/Status/Sponsor: Unknown phase; RECRUITING; Nationwide Children's Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma is being studied. Conditions: Childhood Astrocytoma, Childhood Diffuse Intrinsic Pontine Glioma, Childhood Diffuse Midline Glioma +2 • Eligibility: Inclusion Criteria: * COHORT A and COHORT B: For the dose escalation phase, patients must be ≥ 12 months and \< 18 years of age at the time…. Goal: This phase I clinical trial studies the side effects and best dose of AZD1390 and to see how well it works when given together with radiation therapy for the treatment of pediatric patients with high grade glioma, diffuse midline glioma or diffuse intrinsic pontine glioma. AZD1390 is in a class of medications called kinase inhibitors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Children's Oncology Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests Lutathera (177Lu-DOTATATE) in people with recurrent or progressive high-grade CNS tumors or meningiomas that show uptake on DOTATATE PET scans. - It has two age-based parts: Phase I for ages 4 to under 12 to find a safe dose, and Phase II for ages 12 to 39 to evaluate anti-tumor activity at the standard adult dose, given IV every 8 weeks for up to 4 cycles (about 8 months). - Eligible participants must have had prior therapy and show DOTATATE PET uptake (Krenning score ≥2) and meet health and organ-function criteria; bulky disease or other exclusionary features may disqualify some patients. - Key exclusions include bulky disease with mass effect, pregnancy or breastfeeding, certain other illnesses, and prior treatment with Lutathera or similar radiopharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests genetic analysis to identify genes involved in pheochromocytoma and paraganglioma and to learn how different mutations relate to the disease. It is for people with pheochromocytoma or paraganglioma, their family members, or those with related conditions. The researchers aim to discover new susceptibility genes and to understand genotype-phenotype relationships to guide diagnosis, surveillance, and genetic screening of relatives. The study is currently recruiting, and people with an unconfirmed diagnosis are excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study compares proton radiotherapy with standard photon radiotherapy for adults with primary brain tumors that have a good prognosis and require focal cranial radiation. It is a randomized trial that will enroll 156 patients and assign them 1:1 to proton or photon therapy to see if proton therapy improves functional survival (time alive without recurrence, death, or radiotherapy-related complications). Eligible participants are adults aged 18–70 with a primary brain tumor (such as low‑grade glioma, ependymoma, meningioma, pituitary tumor, schwannoma, or craniopharyngioma) who have an estimated life expectancy over 5 years and a reasonable performance status, and who are planned for focal cranial radiotherapy. Exclusion criteria include prior re-irradiation, palliative radiotherapy, multifocal disease, planned whole-brain or craniospinal irradiation, and planned hypo-fractionated or stereotactic radiotherapy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

FearLess in NeuroOncology is being studied. Conditions: Primary Malignant Brain Tumor, Glioblastoma (GBM), Astrocytoma +2 • Eligibility: Inclusion Criteria: Patients: * Self-report a diagnosis of a primary malignant brain tumor (grade II-IV) * \>2 weeks post-cranial resection or biopsy * Elevated Fear of Recurrence Distress…. Goal: The overarching goal of this project is to assess the feasibility, acceptability, and appropriateness of recruitment methods, target population, and a waitlist design to finalize the protocol of FearLess in primary malignant brain tumor patients and caregivers Phase/Status/Sponsor: Unknown phase; RECRUITING; Virginia Commonwealth University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases is being studied. Conditions: Glioblastoma (GBM), Brain Metastasases • Eligibility: Inclusion Criteria: * 1\. Diagnosed with: (a) GBM according to the 2021 WHO criteria, who have progressed on or following standard of care therapy, including maximal safe resection…. Goal: This will be an open-label Phase 0/1 study that will enroll approximately 15 participants, 9 participants with recurrent WHO Grade 4 glioma (rGBM) and 6 participants with brain metastases, who will receive the investigational drug risvutatug rezetecan (GSK5764227), a B7-H3-targeted antibody-drug conjugate (ADC) with the GSK5757810 payload. The trial will consist of a Phase 0 component (subdivided into Arms A and B) and an Expansion Phase 1 component. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Nader Sanai.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide is being studied. Conditions: Glioblastoma, IDH-wildtype • Eligibility: Inclusion Criteria: 1. Provision of signed informed consent for selection and treatment phase obtained from the patient/legal representative prior to performing any protocol-related procedures, 2. Patients must be…. Goal: Tailored approaches targeting crucial oncogenes and pathways have shown successful results in a number of cancer types and offer exciting perspective in neuro-oncology. IDH (Isocitrate dehydrogenase) wild-type (IDHwt) glioblastoma (GBM) (10%) present a unique and homogenous energetic metabolism which is specifically dependent on the oxidative phosphorylation (OXPHOS) rather than on the aerobic glycolysis. Phase/Status/Sponsor: Unknown phase; RECRUITING; Hopital Foch.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma is being studied. Conditions: Glioblastoma, IDH-wildtype, Metformin, Malignancies • Eligibility: Inclusion Criteria: * Patients with newly diagnosed histologically confirmed GBM (WHO grade IV, IDH wild type) undergoing surgical resection; * hypomethylation or hypermethylation of MGMT assessed post-surgery; *…. Goal: About 75% of CNS malignant tumors are classified as gliomas and the IDH-wildtype glioblastoma (GBM) represents the most aggressive form among CNS malignancies. This is a nationwide single-center phase II drug clinical trial with an approximate duration of 32 months. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Milano Bicocca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 is being studied. Conditions: Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma +11 • Eligibility: Inclusion Criteria: * Frozen biopsy consistent with glioma by neuropathologist at the time of the first surgery in this longitudinal trial. Biopsy confirmation of glioma or infiltrative glioma…. Goal: This research study is evaluating an investigational drug, an oncolytic virus called rQNestin34.5v.2. This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug as a possible treatment for this diagnosis of recurrent or progressive brain tumor. Phase/Status/Sponsor: Unknown phase; RECRUITING; Dana-Farber Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138) is being studied. Conditions: Glioma, Glioblastoma, Brain Tumor • Eligibility: Inclusion Criteria: 1. Patients with radiographic evidence of suggestive of a primary high-grade glioma 2. Brain MRI with contrast demonstrates an enhancing mass within 60 days prior to…. Goal: The purpose of this study is to evaluate the treatment regimen of using Laser Interstitial Thermal Therapy (LITT) and Hypo-fractionated Radiation Therapy to treat patients with newly diagnosed gliomas. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Maryland, Baltimore.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients is being studied. Conditions: Glioblastoma Multiforme, Glioblastoma, Glioblastoma Multiforme, Adult +5 • Eligibility: Inclusion Criteria: 1. Male or female patients ≥ 18 years of age at the time of study enrollment. 2. Body mass index (BMI) ≥ 17 kg/m2. 3. Patients…. Goal: This will be a prospective, randomized, standard of care (SoC) controlled, parallel, open-label, multicenter pivotal study to investigate the efficacy and safety of Bevacizumab (BEV) in combination with or without microbubble (MB)-mediated FUS in patients with recurrent GBM. BEV represents the physician's best choice for the standard of care in rGBM after previous treatment with surgery (if appropriate), standard radiotherapy with temozolomide chemotherapy, and with adjuvant temozolomide. Phase/Status/Sponsor: Unknown phase; RECRUITING; NaviFUS Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma is being studied. Conditions: Glioma, Malignant, Glioblastoma, Glioblastoma Multiforme +4 • Eligibility: Inclusion Criteria: 1. Subject is a male or female 18 years of age or older. 2. Subject is undergoing planned resection of known or suspected GBM. 3. Subject…. Goal: This single center, single arm, open-label, phase 2 study will assess the safety and efficacy of a pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multifome (GBM) patients. The objective of the Phase 2 study is to demonstrate that this surgical technique is safe and effective in a human cohort of patients with resected newly diagnosed AA or GBM and may improve progression-free survival (PFS) and overall survival (OS). Phase/Status/Sponsor: Unknown phase; RECRUITING; Northwell Health.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203) is being studied. Conditions: Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype +1 • Eligibility: Inclusion Criteria: 1. Age ≥18 years and ≤90 years 2. Tumor diagnosed as HGG (WHO grade III/IV) on MRI as assessed by the neurosurgeon 3. Written informed consent…. Goal: There is no consensus on the optimal treatment of patients with high-grade glioma, especially when patients have limited functioning performance at presentation (KPS ≤70). Therefore, there are varied practice patterns around pursuing biopsy, resection, or palliation (best supportive care). Phase/Status/Sponsor: Unknown phase; RECRUITING; Jasper Gerritsen.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This is a prospective randomized controlled trial testing whether omitting preoperative alpha-adrenergic blockade is safe and effective for normotensive pheochromocytoma. - It compares two groups of adults undergoing unilateral total adrenalectomy: one group receives phenoxybenzamine 2–5 weeks before surgery, and the other group receives no preoperative alpha-blockade. - The study aims to learn how omitting the blockade affects intraoperative blood pressure control and overall perioperative hemodynamics. - Eligible participants are adults aged 19–70 with unilateral normotensive pheochromocytoma/paraganglioma; key exclusions include hypertension or antihypertensive treatment, pregnancy, bilateral tumors, suspected malignancy or metastasis, and certain cardiovascular or cerebrovascular conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-3 (UNITED-3) is being studied. Conditions: Glioblastoma Multiforme, Adult • Eligibility: Inclusion Criteria: * Histopathologically confirmed, based on biopsy or surgical resection, glioblastoma, or grade 4 astrocytoma, as defined by the World Health Organization (WHO) * Deemed clinically appropriate…. Goal: The goal of this study is to test whether an adaptive radiation therapy (RT), two-phase approach in participants with glioblastoma impacts local control compared to standard non-adaptive RT approach. The main questions of the study are to see how this adaptive, two-phase RT approach compares to standard RT in terms of: * Local control * Overall and progression-free survival * Patterns of failure * Toxicity, Neurological Function, and Quality of Life Phase/Status/Sponsor: Unknown phase; RECRUITING; Sunnybrook Health Sciences Centre.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests PET imaging using a radioactive form of methionine to evaluate tumors in children and young adults with cancer. It aims to find out how often MET PET can visualize tumors at diagnosis and whether MET uptake relates to tumor grade. The study also looks at how MET distributes in normal organs and how MET PET findings compare with MRI and FDG-PET CT over time. The trial is sponsored by St. Jude Children’s Research Hospital and is currently active but not recruiting. Eligible participants are patients under St. Jude care with known or suspected cancer; key exclusions include having more than six MET PET scans in the past year or an inability to give informed consent (and lactation in women of childbearing age).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Longitudinal Analysis of the Health-related Quality of Life in Glioma Patients is being studied. Conditions: Glioma of Brain • Eligibility: Inclusion criteria: * age ≥ 18 years * patients diagnosed and treated for a high- or low grade glioma * treatment in UZ Leuven. Goal: Gliomas are the most common primary intracranial tumors, representing at least 75% of all primary malignant brain tumors. Histopathologically, gliomas are classified into different subgroups including astrocytomas (60-70%), oligodendrogliomas (10-30%), ependymomas (\<10%) and mixed gliomas (i.e. Phase/Status/Sponsor: Unknown phase; RECRUITING; Universitaire Ziekenhuizen KU Leuven.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors is being studied. Conditions: Glioma, Cholangiocarcinoma, Solid Tumor +1 • Eligibility: Inclusion Criteria: * Provision of informed consent prior to any study specific procedures. * Must be ≥ 18 years. * Body weight \> 30 kg. * For Cohort…. Goal: This is a phase 2 study of the combination of drugs olaparib and durvalumab for the treatment of isocitrate dehydrogenase or (IDH) mutated solid tumors. The purpose of this study is to assess the efficacy of the drug combination via overall response rate and overall disease control rate. Phase/Status/Sponsor: Unknown phase; RECRUITING; University Health Network, Toronto.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests how fractionated brain radiotherapy affects brain tissue and cognitive function in people with primary brain tumors. It will enroll adults (18+) who will receive fractionated partial brain radiotherapy and have decent functional status (KPS ≥70) with at least one year expected survival. Participants will have MRI scans and neurocognitive tests before treatment and at 3, 6, and 12 months after treatment to track brain changes and cognitive outcomes. The goal is to identify brain regions and dose-related changes related to cognitive effects, to help design future cognitive-sparing radiotherapy. Exclusions include the inability to undergo contrast MRI and prior brain radiotherapy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests a new immune therapy approach for children and young adults with recurrent high-grade glioma or newly diagnosed DIPG/DMG: CD200AR-L given with the GBM6-AD vaccine, plus imiquimod cream and a single dose of radiation. - It is a Phase I, single-center trial to find the maximum tolerated dose of CD200AR-L when used with a fixed dose of GBM6-AD and to learn about the treatment’s side effects. - The trial will enroll people aged 2 to 25 who have recurrent HGG or newly diagnosed DMG/DIPG and meet certain health criteria. - Key exclusions include known allergy or sensitivity to the study components (GBM6-AD, CD200AR-L, or imiquimod), diffuse leptomeningeal disease, uncontrolled illness, recent cancer treatment, pregnancy, or ongoing immune-suppressive therapy. - The researchers aim to use safety data to plan a larger study to assess whether this combination can be effective against pediatric gliomas.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests a new planning approach for proton beam radiotherapy in adults with low-grade glioma who need radiotherapy. - It uses individualized, model-guided optimization to estimate and try to reduce the risk of late MRI-contrast–enhancing brain lesions after treatment. - The goal is to find out whether this model-based planning tool can be feasibly used in actual clinical planning to lower this risk. - Eligible participants are adults over 18 with histologically confirmed low-grade glioma requiring definitive or adjuvant radiotherapy; exclusions include prior brain irradiation, contraindication for contrast-enhanced MRI, neurofibromatosis, or participation in another competing trial. - The trial is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: * Age ≥ 18 years * Histological confirmation of one of the following: * Glioblastoma, IDH-wildtype * Grade 3 or 4 IDH1/2 mutant astrocytoma (2021 WHO…. Goal: The purpose of this study is to test WSD0628 in combination with radiation therapy for recurrent brain tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Mayo Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests the combination of nivolumab and ipilimumab in adults with rare cancers to see if it can shrink tumors or slow their growth. - It includes many different rare tumor types in separate groups, plus a PD-L1–amplified cohort that uses nivolumab alone, and it measures how often tumors respond using standard criteria. - The trial also looks at safety, overall survival, and progression-free survival across cohorts. - Eligible participants must have progressed after prior therapy and generally cannot have active brain metastases or uncontrolled autoimmune disease; some cohorts have additional specific requirements or exclusions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests olaparib, a drug that may slow tumor growth, in adults with glioma, cholangiocarcinoma, or other solid tumors that have IDH1 or IDH2 mutations and have progressed after standard treatment. - Participants are grouped into three cohorts: glioma, cholangiocarcinoma, and other IDH-mutant solid tumors, to see how they respond to olaparib. - The study aims to learn the overall response rate, how long patients live without the disease getting worse, overall survival, duration of responses, and the safety of olaparib alone. - Researchers will measure blood and tumor markers, including a molecule called 2HG, to see if these relate to treatment response. - Key exclusions include active uncontrolled brain metastases, prior PARP inhibitor therapy, pregnancy, HIV infection on antiretroviral therapy, and other serious medical conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This pediatric MATCH trial tests the drug ivosidenib (AG-120) in children and adolescents with advanced solid tumors, CNS tumors, lymphomas, or histiocytic disorders that have IDH1 mutations and have not responded to prior treatment. The study aims to see how often tumors shrink or disappear (objective response rate) and to learn about progression-free survival and safety in this group. Participants are aged 12 months to 21 years and must have measurable disease along with other health criteria. Ivosidenib is given by mouth once daily in 28-day cycles, for up to 2 years, to study its pharmacology and biomarkers of response. Key exclusions include pregnancy or breastfeeding, use of strong CYP3A4 inhibitors or inducers, prior exposure to IDH1 inhibitors, and receiving another investigational or anti-cancer drug at enrollment.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Extensive Resection of Malignant Brain Tumors Using Advanced Imaging Techniques is being studied. Conditions: Glioblastoma, Astrocytoma, IDH-Mutant, Grade 4 • Eligibility: Inclusion Criteria: * Age ≥ 18 years * New clinical and radiological suspected diagnosis of IDH-wildtype glioblastoma or grade IV IDH-mutant astrocytoma * Visible FET PET uptake in…. Goal: Rationale: Patients with IDH-wildtype glioblastoma or grade IV IDH-mutant astrocytoma have a very poor prognosis despite standard treatment consisting of surgery, radiotherapy, and chemotherapy. Diffuse infiltration of the brain by the tumor is thought to be one of the main causes of this therapy-resistance. Phase/Status/Sponsor: Unknown phase; RECRUITING; Amsterdam UMC, location VUmc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests whether B7-H4 in macrophages contributes to resistance to glioma vaccines and whether interfering with the B7-H4 axis could improve vaccine response. - It is for adults with glioma treated at Huashan Hospital (ages 18–80) who meet tissue-sampling and pathology criteria and provide informed consent; pregnant women and those in other trials are excluded. - Researchers will use cells, organoids, and animal models and will include a dendritic cell vaccine to see if blocking B7-H4 can reverse vaccine resistance and boost signals that attract T cells. - The team aims to build a model to evaluate the clinical benefits of vaccine strategies in glioma using B7-H4 expression and other clinical features.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients is being studied. Conditions: Glioblastoma, Glioma, Glioblastoma Multiforme +1 • Eligibility: Inclusion Criteria: 1a. Arm C only: Participants undergoing resection for a suspected newly diagnosed WHO Grade 4 glioma. Participants will also need to have radiation planned as part…. Goal: This is an open-label, single-center Phase 0/1b study that will enroll at least 27 participants with recurrent WHO Grade 4 Glioma requiring re-radiation and approximately 35 participants with newly-diagnosed WHO Grade 4 glioma (nGBM). The trial will be composed of a Phase 0 component (subdivided into Arms A - C), and an expansion Phase 1b. Phase/Status/Sponsor: Unknown phase; RECRUITING; Nader Sanai.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype is being studied. Conditions: Glioma, Glioblastoma, High Grade Glioma +2 • Eligibility: * INCLUSION CRITERIA: * Patients must have recurrent diffuse glioma (histologically confirmed by National Institutes of Health (NIH) Laboratory of Pathology) with isocitrate dehydrogenase 1 (IDH1) or isocitrate…. Goal: Background: Gliomas are the most common malignant brain tumors. Some have certain changes (mutations) in the genes isocitrate dehydrogenase 1 (IDH1) or isocitrate dehydrogenase 2 (IDH2). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Recombinant Human Endostatin Combined with Temozolomide and Irinotecan in Recurrent Gliomas is being studied. Conditions: Glioblastoma, Recurrent, Lower Grade Glioma, Recurrent • Eligibility: Inclusion Criteria: 1. Age ≥ 18 and ≤70; 2. Histopathologically-confirmed, supratentorial GBM or lower-grade gliomas (such as oligodendroglioma, astrocytoma, oligoastrocytoma, anaplastic astrocytoma, anaplastic oligodendroglioma or anaplastic oligoastrocytoma); 3.…. Goal: Almost all gliomas relapse. After temozolomide rechallenge or combination with irinotecan, the progression-free survival rate at 6 months (PFS-6%) of recurrent glioblastoma was about 21%. Phase/Status/Sponsor: Unknown phase; RECRUITING; Beijing Sanbo Brain Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow is being studied. Conditions: Diffuse Glioma, Glioblastoma, Adaptive Radiotherapy +1 • Eligibility: Inclusion Criteria: * Histological diagnosis of diffuse glioma. Patients with IDH-negative GBM (stratum A) and IDH-mutant glioma (astrocytoma or oligodendroglioma) need radiotherapy (stratum B). Age: 18-70 years. Karnofsky…. Goal: Gliomas are common primary brain tumors in adults. Gliomas can be classified into different types based on tumor grade, histopathological features, and molecular characteristics. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Tata Memorial Centre.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas is being studied. Conditions: Glioblastoma, IDH1 Gene Mutation, IDH2 Gene Mutation +7 • Eligibility: Inclusion Criteria: * Arm A Only: Participants must have histologically confirmed World Health Organization (WHO) grade III-IV newly diagnosed IDH1/2-mutant glioma. * Arm B Only: WHO grades I-IV…. Goal: This phase I trial studies the side effects and best dose of BGB-290 and temozolomide in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma that is newly diagnosed or has come back. BGB-290 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University of California, San Francisco.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This pediatric MATCH trial tests selpercatinib, an RET pathway inhibitor, in children and adolescents with advanced solid tumors, lymphomas, or histiocytic disorders that have activating RET gene alterations. The study aims to learn how often tumors shrink or disappear (objective response rate) and how long patients stay progression-free, as well as how tolerable the drug is. Participants are ages 12 months to 21 years with measurable disease and must have recovered from prior therapy; they must not have previously received selpercatinib or other RET inhibitors. Selpercatinib is given by mouth twice daily in 28-day cycles for up to 26 cycles (about 2 years), with regular imaging and safety monitoring. Key exclusions include pregnancy, certain drug interactions (e.g., strong CYP3A4 inhibitors/inducers), recent major surgery, active infection, and uncontrolled medical conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This pediatric MATCH trial tests tipifarnib in children and young people aged 12 months to 21 years whose advanced solid tumors, lymphoma, or histiocytic disorders have an HRAS gene alteration. - The main goal is to see how many patients have a tumor shrinkage or disappearance (objective response) with tipifarnib. - The study also looks at progression-free survival and how well the drug is tolerated in kids and teens. - It will explore biomarkers that might predict who responds and how tumor DNA in blood changes over time. - Key exclusions include pregnancy or breastfeeding, and not being eligible if you’re on other investigational drugs or certain interacting medications.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a Phase I/IIa study of C5252 for intracranial tumors. It tests safety and tolerability and looks for early signs of activity in adults with recurrent high-grade glioma who have had standard therapy and can receive C5252 through a surgically implanted Ommaya reservoir into the tumor cavity. The trial uses a dose-escalation phase followed by a dose-expansion phase to learn about safety, toxicity, and preliminary efficacy. Key exclusions include inability to have an MRI, active brain hemorrhage, infections or recent immune-suppressing therapy, and having another active cancer or certain prior treatments; the study is not yet recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM is being studied. Conditions: Glioma, Malignant • Eligibility: Inclusion Criteria 1. Age ≥ 18 years of age 2. Newly diagnosed Isocitrate dehydrogenase (IDH) wild type (CARIS result), MGMT promoter unmethylated (CARIS result) WHO grade IV glioma…. Goal: This is a phase 1b study of P30-linked EphA2, CMV pp65, and survivin vaccination (collectively called the P30-EPS vaccine) in HLA-A\*0201 positive patients with a newly diagnosed, unmethylated, and untreated World Health Organization (WHO) grade IV malignant glioma. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Mustafa Khasraw, MBChB, MD, FRCP, FRACP.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas is being studied. Conditions: Newly Diagnosed H3-mutated Glioma • Eligibility: Inclusion Criteria: * Patients present with histologically confirmed diagnosis of an H3.1K27M or H3.3K27M-mutated diffuse midline glioma WHO grade IV (with or without measurable residual tumor after tumor…. Goal: The study "A MultIceNTER Phase I Peptide VaCcine Trial to Exploit NeoePitope-Specific T Cells for the Treatment of H3K27M-Mutated Gliomas - (INTERCEPT H3)" is a non-controlled, open-label, single arm, multicenter phase I trial involving patients with gliomas carrying an H3.1K27M or H3.3K27M mutation. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; German Cancer Research Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

GammaTile and Stupp in Newly Diagnosed GBM is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: 1. All patients must be ≥ 18 years of age 2. Histopathological and molecular confirmation of newly diagnosed GBM using IDH mutation testing (such as immunohistochemistry…. Goal: In summary, standard of care postoperative chemoradiation for patients with newly diagnosed GBM does not routinely provide durable local control or prolonged overall survival. As discussed above it seems unlikely that patient outcomes will be significantly improved with radiation dose escalation given at the time of the EBRT boost. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; GT Medical Technologies, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma is being studied. Conditions: Medulloblastoma, Glioblastoma Multiforme, Anaplastic Astrocytoma +5 • Eligibility: Screening Inclusion Criteria: * • DIAGNOSIS: Patients with a histologically confirmed diagnosis of a primary CNS tumor that is progressive or recurrent defined as radiographic progression in any…. Goal: Patients will receive a vaccine called SurVaxM on this study. While vaccines are usually thought of as ways to prevent diseases, vaccines can also be used to treat cancer. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Pediatric Brain Tumor Consortium.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options is being studied. Conditions: Solid Tumors, CNS Tumors • Eligibility: Inclusion Criteria: 1. Disease status: * Phase 1 portion (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 * Phase 2 portion: * Part…. Goal: This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Hoffmann-La Roche.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab is being studied. Conditions: Glioblastoma, Glioblastoma Multiforme (GBM) • Eligibility: Inclusion Criteria: * \> 18 year of age * ECOG 0-2 * Able to provide informed consent for the study * Minimum of 1 month from completion of…. Goal: This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Royal North Shore Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma is being studied. Conditions: Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor +5 • Eligibility: Inclusion Criteria: All Patients * Previously confirmed (histologically or cytologically) pediatric solid tumor (e.g., neuroblastoma, sarcoma), lymphoma (including Hodgkin's lymphoma), or malignant brain tumors that are clinically or…. Goal: The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment options with curative potential. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Cellectar Biosciences, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Patient-derived Glioma Stem Cell Organoids is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: * MRI imaging suggestive for glioblastoma * \> 18 years of age Exclusion Criteria: * Karnofsky index \< 70 * Clotting disorders * Neurosurgical contraindications for…. Goal: Rationale: Glioblastoma (GM) is the most frequent incurable adult brain tumor with median survival of 15 months after diagnosis, despite extensive treatment with surgery, radiation therapy and chemotherapy. Tumor recurrence is inevitable after which life prolonging therapies are no longer available. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Maastricht Radiation Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Biopsy Versus Resection in Elderly Glioblastoma Patients. A Prospective Cohort Study. is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: 1. Age ≥70 years 2. Tumor diagnosed as glioblastoma on MRI with distinct ring-like pattern of contrast enhancement with thick irregular walls and a core area…. Goal: This trial is set up as a prospective observational cohort study to identify if either biopsy or resection should be the surgical modality of choice in elderly glioblastoma patients with a newly diagnosed tumor. Patients who are considered eligible for GBM resection or biopsy will be included. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Erasmus Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study for Cerebral Open Flow Microperfusion is being studied. Conditions: Glioma, Glioblastoma • Eligibility: Inclusion Criteria * ECOG performance status (PS) 0, 1 or 2. * Clinical and radiographic evidence diagnosis of glioma, or a prior diagnosis of glioma (suspected WHO grade…. Goal: The purpose of this study is to evaluate the safety and feasibility of intra-operative microperfusion during a planned neurosurgical resection of diseased brain parenchyma, including either an epileptic focus requiring temporal lobectomy or a glioma. Devices used for microperfusion are Joanneum Research cerebral open flow microperfusion (OFM) catheters, push and pull tubing, and MPP102-II pump. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Mayo Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests a treatment plan for children with diffuse midline gliomas that combines temozolomide and the anti-angiogenesis drug anlotinib with radiotherapy, followed by maintenance therapy including temozolomide, ongoing anlotinib, and a PD-L1 inhibitor. - It aims to find out whether this approach can improve progression-free survival and will also look at response rate, two-year overall survival, quality of life, and safety. - Participants are children aged 3 to 18 with pathologically confirmed DMG who have not had prior specialized treatment and have at least one measurable lesion, with adequate organ function and consent. - Key exclusions include prior anti-tumor treatment for DMG, active infections, immune deficiencies, hepatitis B or C infections, significant heart problems, or other conditions that could affect safety or study completion. - The study is not yet recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

DOTATOC PET/CT for Imaging NET Patients is being studied. Conditions: Neuroendocrine Tumors, Insulinoma, Gastrinoma +13 • Eligibility: Inclusion Criteria: All subjects: * World health organization performance status 0-2 * Able to provide written informed consent/assent (or consent by guardian for subjects \<19 years) * Patients…. Goal: Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of special molecules called somatostatin receptors (SSTR). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; British Columbia Cancer Agency.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Immuno-Positron Emission Tomography (PET)-Glioma Study, a Proof-of-principle Imaging Study is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: * Patients with a new probable diagnosis of glioblastoma based on MRI imaging. * prior to initiation of specific tumor therapy and prior to any surgery…. Goal: Imaging of proinflammatory activated microglia by Purine 2X7 (P2X7) receptor scintigraphy in Positron Emission Tomography (PET) scanner in Glioblastoma patients. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Kepler University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients is being studied. Conditions: Glioblastoma Multiforme, Meningioma • Eligibility: Inclusion Criteria * One prior resection of histologically-diagnosed World Health Organization (WHO) Grade III or IV glioma, or WHO grade II or III meningioma. * MRI evidence of…. Goal: In the proposed trial, patients will be administered ribociclib prior to surgical resection of their tumor. Patients will be enrolled in time-intervals sequentially (non-randomized). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Nader Sanai.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma is being studied. Conditions: High-grade Glioma, Oligodendroglioma, Astrocytoma +1 • Eligibility: Inclusion Criteria: 1. Confirmed recurrent gliomas that were originally diagnosed as high-grade glioma (World Health Organization \[WHO\] Grade 3 or 4; astrocytoma, oligodendroglioma, or glioblastoma) by histopathology or…. Goal: This is a phase 1 open-label, multicenter study to investigate tolerability, safety and PK properties of oral OKN-007 in patients with recurrent high-grade glioma. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Oblato, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Prediction of Myocardial Injury After Laparoscopic Pheochromocytoma/ParaGangLioma Resection is being studied. Conditions: PGL • Eligibility: Inclusion Criteria: * Scheduled for Laparoscopic PPGL resection Exclusion Criteria: 1. Open or laparoscopic conversion to open PPGL resection was excluded 2. Cardiac paraganglioma was excluded 3. History…. Goal: This observational study was conducted in patients undergoing elective laparoscopic pheochromocytoma/paraganglioma(PPGL) resection. It mainly answers the following two main questions: 1. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Peking Union Medical College Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013) is being studied. Conditions: Glioblastoma WHO Grade IV, Diffuse Midline Glioma Histone 3 K27M WHO Grade IV, Anaplastic Astrocytoma WHO Grade III +2 • Eligibility: Inclusion Criteria: * Newly diagnosed, previously untreated diffuse paediatric high grade glioma with central neuropathological review including paedHGG (WHO grade IV) and anaplastic astrocytoma (WHO grade III). *…. Goal: The HIT-HGG-2013 trial offers an innovative high-quality diagnostics and science program for children and adolescents \>3 years, suffering from one of the following types of high grade gliomas: 1. glioblastoma WHO grade IV (GBM) 2. Phase/Status/Sponsor: Unknown phase; UNKNOWN; University of Göttingen.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Functional and Ultrasound Guided Resection of Glioblastoma is being studied. Conditions: Glioma Glioblastoma Multiforme • Eligibility: Inclusion Criteria: * Age 18-70 years * Neuro-oncology Multi-Disciplinary Team (MDT) decision that the imaging shows a primary GB tumour which is maximally resectable (attempted gross total resection…. Goal: Functional and ultrasound-guided resection of glioblastoma: assessing the use of additional imaging during surgery to improve outcomes for patients with glioblastoma brain tumours Phase/Status/Sponsor: Unknown phase; UNKNOWN; University of Oxford.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer is being studied. Conditions: Glioblastoma Multiforme, Glioblastoma, GBM +4 • Eligibility: Inclusion Criteria: All patients must meet the following inclusion criteria. All tests and eligibility criteria must be completed within four weeks of completion of radiation and chemotherapy, following…. Goal: The primary purpose of the study is to determine the efficacy of an investigational therapy called DCVax(R)-L in patients with newly diagnosed GBM for whom surgery is indicated. Patients must enter screening at a participating site prior to surgical resection of the tumor. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Northwest Biotherapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Educating Brain Tumor Patients Using Patient-specific Actual-size Three-dimensional Printed Models is being studied. Conditions: Brain Tumor, Glioma, Glioblastoma +5 • Eligibility: Inclusion Criteria: * Patient with a brain tumor * functional imaging (MRI, functional MRI (fMRI) and Diffusion Tensor Imaging (DTI)) requested for pre-operative planning Exclusion Criteria: * Inadequate…. Goal: Patient education plays an essential role in patient-centered care as it enhances patient satisfaction and information comprehension. However, about 40-80% of the information patients receive from healthcare professionals is forgotten and about half of the information patients remember is incorrect. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Sümeyye Sezer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery is being studied. Conditions: Brain and Central Nervous System Tumors • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed supratentorial malignant glioma of 1 of the following types: * Glioblastoma multiforme * Gliosarcoma * Anaplastic astrocytoma * Anaplastic oligodendroglioma * Anaplastic mixed…. Goal: RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Northwestern University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

V-Boost Immunotherapy in Glioblastoma Multiforme Brain Cancer is being studied. Conditions: Glioblastoma Multiforme, Glioma of Brain • Eligibility: Inclusion Criteria: * Confirmed diagnosis of GBM * ≥ 5 years of age * Consent from parents or legal guardian if under-aged Exclusion Criteria: * Severe pulmonary, cardiac…. Goal: The Phase II study to determine the safety and efficacy of V-Boost in treating a type of brain cancer called Glioblastoma Multiforme (GBM). V-Boost is an immunotherapy in which the patient's immune system will be modulated to eliminate tumor cells. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Immunitor LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The PIONEER Initiative is testing a system to provide functional precision medicine testing on a patient’s tumor tissue, which can include organoid drug screening and genomic profiling to help guide therapy decisions. It is for all cancer patients and for people at risk of cancer, at any medical facility, with tumor tissue collected at biopsy or surgery and stored for current or future testing. The study aims to learn whether researchers can return the test results to the patient and their clinicians, and whether this information provides added benefit over standard care. Exclusions include patients who decline definitive therapies, those with comorbidities that prevent definitive therapies, and patients on hospice.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients. is being studied. Conditions: Glioblastoma, Glioma, Neoplasms, Neuroepithelial +5 • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years; Male or Female. 2. Treatment-naïve patients after Resection of Glioblastoma. 3. Histologically confirmed Glioblastoma. 4. KPS ≥ 60 5. White blood…. Goal: A multi-center, open-label, single-arm, phase I/II clinical study is designed to test the safety and immunogenicity of an investigational Dendritic and Glioma Cells Fusion vaccine given with IL-12 for treatment-naïve patients after resection of glioblastoma. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Second Affiliated Hospital, School of Medicine, Zhejiang University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Large-scale Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96 is being studied. Conditions: Glioma of Brain • Eligibility: Inclusion Criteria: 1. Able to read and understand the informed consent document; must sign the informed consent; 2. Aged 18 to 75 years old , sex is not…. Goal: This trial is to further study the safety and effectiveness of autologous gp96 treatment of glioblastoma on the basis of preliminary work. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Cure&Sure Biotech Co., LTD.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests an oral drug called AG-120 (ivosidenib) in people with IDH1-mutated advanced solid tumors, including glioma. It enrolls adults whose disease has recurred or progressed after standard therapy and includes several expansion groups such as cholangiocarcinoma, chondrosarcoma, non-enhancing glioma, and other IDH1-mutated tumors. The study first uses a dose-escalation phase to find the maximum tolerated dose and a recommended Phase II dose, then expands at that dose to evaluate safety, tolerability, and any signs of clinical activity. The trial aims to learn how safe the drug is, how it behaves in the body, and whether it shows anticancer activity at the chosen dose. Key exclusions include recent anticancer therapy or investigational agents, certain heart conditions or QT prolongation risk, pregnancy, and untreated or recently treated brain metastases.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Multispectral Bimodal Fluorescence Guided Surgery of High-grade Glioma With Cetuximab-800CW and 5-ALA (5-aminolevulinic Acid) is being studied. Conditions: Glioblastoma, High-grade Glioma • Eligibility: Inclusion Criteria: * Willing to adhere to the prohibitions and restrictions specified in this protocol. * Capable of giving signed informed consent (voluntarily), indicating that the patient understands…. Goal: The MIRROR study is a prospective, single center phase I feasibility and dose finding study in patients with high-grade glioma, to establish the safety, feasibility, and optimal dosage of Cetuximab-IRDye800CW for fluorescence guided surgery, in comparison to the standard of care (SOC), 5-ALA fluorescent imaging agent. The main research objectives of this study are: 1. Phase/Status/Sponsor: Unknown phase; UNKNOWN; University Medical Center Groningen.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1) is being studied. Conditions: Recurrent Malignant Glioma, Glioblastoma Multiforme of Brain, Gliosarcoma of Brain +1 • Eligibility: Inclusion Criteria: Patients must have histologically or cytologically confirmed recurrent/progressive glioblastoma multiforme, anaplastic astrocytoma, or gliosarcoma. Prior therapy. Patients must have failed a course of external beam radiotherapy…. Goal: The purpose of this study is to determine how safe and how well-tolerated the experimental study drug, C134 is when re-administered into the brain where the tumor is located. Phase/Status/Sponsor: Unknown phase; TERMINATED; University of Alabama at Birmingham.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Safety and Effectiveness of NV-A01 in Glioma Patients is being studied. Conditions: Advanced Glioblastoma Patients • Eligibility: Inclusion Criteria: 1. Patients with advanced malignant glioma confirmed by histopathology; 2. Patients who have received radiotherapy and/or temozolomide (TMZ) treatment and have residual or recurrent tumors; 3.…. Goal: The goal of this clinical trial is to learn about the safety and effectiveness of NV-A01 in the treatment of advanced glioma patients. The main questions it aims to answer are: 1. Phase/Status/Sponsor: Unknown phase; UNKNOWN; First Affiliated Hospital of Wannan Medical College.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting is being studied. Conditions: Glioma, Glioblastoma, Glioblastoma Multiforme +2 • Eligibility: General Inclusion Criteria: * Patient must willingly provide written consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits,…. Goal: The purpose of this phase 2, two arm, biomarker-driven study is to determine if treatment of O-6-methylguanine-DNA methyltransferase (MGMT) unmethylated glioblastoma with VAL-083 improves overall survival (OS), compared to historical control, in the adjuvant or recurrent setting. Phase/Status/Sponsor: Unknown phase; COMPLETED; Kintara Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

FET-PET/MRI Based Treatment Planning for Glioblastoma Multiforme in Post-Surgical Patients (FET-TREAT) is being studied. Conditions: Glioblastoma Multiforme • Eligibility: Inclusion Criteria: Each participant must meet all of the following inclusion criteria to participate in this study: * ≥ 18 years of age * Diagnosis of glioblastoma multiforme…. Goal: Glioblastoma multiforme (GBM) represent the most common primary brain malignancy and prognosis remains poor. The most common subtype is glioblastoma which has a 5-year survival rate of approximately 5%. Phase/Status/Sponsor: Unknown phase; COMPLETED; Sunnybrook Health Sciences Centre.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Glioblastoma and Individualized Therapies is being studied. Conditions: Glioma, Malignant • Eligibility: Inclusion Criteria: * malignant glioma, IDH WT Exclusion Criteria: * na. Goal: The treatment of patients with World Health Organization (WHO) grade 4 malignant glioma has not seen any significant breakthrough the past years. Following surgery and radio / chemotherapy patients still experience a very high recurrence risk and the prognosis is dismal. Phase/Status/Sponsor: Unknown phase; AVAILABLE; Zentrum fur Humangenetik Tuebingen.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas is being studied. Conditions: Glioma, Malignant • Eligibility: Inclusion Criteria: * Patients must have operable brain tumor presumed to be high grade glioma (HGG) based on clinical and radiologic evaluation, where a gross total surgical resection…. Goal: The purpose of this phase I trial is to test the safety of combining GMCI, an immunostimulator, plus nivolumab, an immune checkpoint inhibitor (ICI), with standard of care radiation therapy, and temozolomide in treating patients with newly diagnosed high-grade gliomas. Gene Mediated Cytotoxic Immunotherapy (GMCI) involves the use of aglatimagene besadenovec (AdV-tk) injection into the tumor site and oral valacyclovir to kill tumor cells and stimulate the immune system. Phase/Status/Sponsor: Unknown phase; COMPLETED; Candel Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma is being studied. Conditions: Brain and Central Nervous System Tumors • Eligibility: Key Inclusion Criteria: All participants 1. Age ≥ 18 years old. 2. Confirmed diagnosis of glioblastoma (WHO Grade IV). 3. Agreement to provide archival tumor tissue for exploratory…. Goal: The primary objective of this study is to evaluate the safety, efficacy and clinical activity of Pamiparib in combination with radiation therapy (RT) and/or temozolomide (TMZ) in participants with newly diagnosed or recurrent/refractory glioblastoma. Phase/Status/Sponsor: Unknown phase; COMPLETED; BeiGene USA, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase 2 Study of ONC201 in Neuroendocrine Tumors is being studied. Conditions: Recurrent Neuroendocrine Tumor, Metastatic Neuroendocrine Tumor • Eligibility: 1. "Subjects must have a unresectable, recurrent, locally advanced, refractory, or metastatic neuroendocrine tumor including pheochromocytoma-paraganglioma (PC-PG), DSRCT, Ewing Sarcoma or PNET, or any neuroendocrine tumor with a…. Goal: The purpose of this study is to learn if a new drug, ONC201 can make tumors become smaller or go away completely. Investigators also want to learn if ONC201 can prevent new deposits of cancer from appearing in new places in participants (metastases). Phase/Status/Sponsor: Unknown phase; COMPLETED; Peter Anderson.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Brain Tumor Intraoperative Ultrasound Database is being studied. Conditions: Brain Tumor, Brain Neoplasms, Brain Cancer +2 • Eligibility: Inclusion Criteria: * Adult patients operated between January 2018 and January 2020 with a pathological diagnosis of WHO grade IV astrocytoma (Glioblastoma). * Intraoperative ultrasound study that includes…. Goal: Predicting the survival of patients diagnosed with glioblastoma (GBM) is essential to guide surgical strategy and subsequent adjuvant therapies. Intraoperative ultrasound (ioUS) is a low-cost, versatile technique available in most neurosurgical departments. Phase/Status/Sponsor: Unknown phase; COMPLETED; Hospital del Rio Hortega.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG is being studied. Conditions: Childhood Glioblastoma • Eligibility: Inclusion Criteria: 1. Diagnosis of relapsed high-grade malignant glioma confirmed by central neuropathological and neuroradiological review (last magnetic resonance imaging diagnosis not older than 4 weeks) - including…. Goal: This phase I/II trials evaluates the feasibility, safety and efficacy of an individualized cancer vaccine, based on autologous, tumor-lysate loaded dendritic cells in children and adolescents with relapsed high-grade gliomas. In addition, regulatory T cells are depleted by a short cycle of metronomic cyclophosphamide upfront of the vaccine in order to facilitate induction of immune responses. Phase/Status/Sponsor: Unknown phase; COMPLETED; Wuerzburg University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas is being studied. Conditions: Pilomyxoid Astrocytoma, Pilocytic Astrocytoma, Glioma, Astrocytic +9 • Eligibility: Inclusion Criteria: 1. Age \> 1 year of age and ≤ 21 years of age 2. Diagnosis 2.1. Group A - Low-grade Glioma Group: Histology: Biopsy-proven: * Pilocytic…. Goal: This is a study to determine the safety and efficacy of the drug, mebendazole, when used in combination with standard chemotherapy drugs for the treatment of pediatric brain tumors. Mebendazole is a drug used to treat infections with intestinal parasites and has a long track record of safety in humans. Phase/Status/Sponsor: Unknown phase; COMPLETED; Julie Krystal.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Imaging Study of GC1008 in Glioma is being studied. Conditions: Primary Brain Tumors • Eligibility: Part 1 Inclusion Criteria * \> 18 years * WHO 0,1,2 * Suspicion of malignant glioma on contrast-enhanced MRI * Able to give written informed consent Exclusion Criteria…. Goal: Brain tumors account for only 2% of all cancers but result in a disproportionate share of cancer morbidity and mortality. The five-year survival rates for the most common histologic subtypes, anaplastic astrocytoma and glioblastoma (glioblastoma multiforme, GBM), are 30% and 10%, respectively. Phase/Status/Sponsor: Unknown phase; COMPLETED; University Medical Center Groningen.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children is being studied. Conditions: Malignant Glioma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma +8 • Eligibility: Inclusion Criteria: * Patients must have a recurrent supratentorial WHO Grade III malignant glioma (anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, anaplastic pleomorphic xanthoastrocytoma, ependymoma) or WHO Grade IV…. Goal: The purpose of the study is to confirm the safety of the selected dose and potential toxicity of oncolytic poliovirus (PV) immunotherapy with PVSRIPO for pediatric patients with recurrent WHO grade III or IV malignant glioma, but evidence for efficacy will also be sought. The primary objective is to confirm the safety of the selected dose of PVSRIPO when delivered intracerebrally by convection-enhanced delivery (CED) in children with recurrent WHO Grade III malignant glioma (anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, anaplastic pleomorphic xanthoastrocytoma) or WHO Grade IV malignant glioma (glioblastoma, gliosarcoma). Phase/Status/Sponsor: Unknown phase; COMPLETED; Istari Oncology, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma is being studied. Conditions: Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma +1 • Eligibility: Inclusion Criteria: * Patients must have presumed resectable or partially resectable malignant glioma based on clinical and radiologic evaluation (pathologic confirmation of malignant glioma must be made at…. Goal: The purpose of this study was to evaluate the safety and potential efficacy of CAN-2409 (also known / previously described as AdV-tk, GMCI) for malignant gliomas. The approach used an adenoviral vector (disabled virus) engineered to express the Herpes thymidine kinase gene (aglatimagene besadenovec, CAN-2409), followed by an antiherpetic prodrug, valacyclovir. Phase/Status/Sponsor: Unknown phase; COMPLETED; Candel Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors is being studied. Conditions: Supratentorial Neoplasms, Malignant, Malignant Glioma, Glioblastoma +4 • Eligibility: Inclusion Criteria: * Age ≥ 36 months and \< 19 years * Pathologically proven malignant supratentorial brain tumor (including glioblastoma multiforme, giant cell glioblastoma, anaplastic astrocytoma, primitive neuroectodermal…. Goal: This study is a clinical trial to determine the safety of injecting G207 (a new experimental virus therapy) into a recurrent or progressive brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication and tumor cell killing, will also be tested. Phase/Status/Sponsor: Unknown phase; COMPLETED; Gregory K. Friedman, MD.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of the Specificity and Sensitivity of 5- Aminolevulinic Acid (ALA) Fluorescence in Malignant Brain Tumors is being studied. Conditions: Brain Neoplasms • Eligibility: Inclusion Criteria: * Patients must have clinically documented primary brain tumor for which resection is clinically indicated. * Age ≥ 18 years. Because no dosing or adverse event…. Goal: Extent of resection is a very important prognostic factor affecting survival in individuals diagnosed with a malignant glioma. However, the infiltrative nature of the malignant glioma tumor cells produces indistinct borders between normal and malignant tissues, and the lack of easily identifiable tumor margins confounds attempts at total resection. Phase/Status/Sponsor: Unknown phase; COMPLETED; Southern Illinois University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Assessing the Effectiveness of 2D Non-Navigated Intraoperative Ultrasound in Glioma Surgery is being studied. Conditions: Glioma, Glioma, Malignant, Low-grade Glioma +2 • Eligibility: Inclusion Criteria: * Adult patients aged 18 years or older. * Patients diagnosed with gliomas, confirmed by a pathologist. * Patients who are scheduled to undergo craniotomy for…. Goal: This retrospective study aims to assess the utility of 2D non-navigated intraoperative ultrasound (ioUS) as a cost-effective alternative for guiding the surgical resection of gliomas and for detecting residual tumor. The study will analyse the records from consecutive adult patients diagnosed with gliomas, undergoing craniotomy between June 2018 and June 2023. Phase/Status/Sponsor: Unknown phase; COMPLETED; Hospital del Rio Hortega.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas is being studied. Conditions: Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma • Eligibility: Inclusion Criteria: * Presumed malignant glioma based on clinical and radiologic evaluation (pathologic confirmation of malignant glioma must be made at the time of stereotactic biopsy or resection…. Goal: This phase I study evaluated a Gene Mediated Cytotoxic Immunotherapy approach for malignant gliomas, including glioblastoma multiforme and anaplastic astrocytoma. The purpose of this study was to assess the safety and feasibility of delivering an experimental approach called GliAtak which uses AdV-tk, an adenoviral vector containing the Herpes Simplex thymidine kinase gene, plus an oral anti-herpetic prodrug, valacyclovir, in combination with standard of care radiation. Phase/Status/Sponsor: Unknown phase; COMPLETED; Candel Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children and Young Adults With High Grade or High-Risk Cancer and Their Caregivers is being studied. Conditions: Glioblastomas, Sarcoma, Astrocytoma +2 • Eligibility: * INCLUSION CRITERIA FOR CHILDREN: * Patients diagnosed with a high-risk/high-grade cancer (e.g., high-grade brain tumors, relapsed/refractory acute lymphoblastic leukemia, acute myeloid leukemia, high-grade sarcoma) characterized by poor…. Goal: Background: People cope with cancer in different ways. Mindfulness means focusing on the present moment with an open mind. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma is being studied. Conditions: Glioma, High Grade Astrocytoma, Glioblastoma Multiforme • Eligibility: Inclusion Criteria: * Age \> 18 * Informed consent * Diagnosis of grade IV glioma with progression following standard treatment. * Must be able to tolerate surgery to…. Goal: TVI-Brain-1 is an experimental treatment that takes advantage of the fact that your body can produce immune cells, called 'killer' white blood cells that have the ability to kill large numbers of the cancer cells that are present in your body. TVI-Brain-1 is designed to generate large numbers of those 'killer' white blood cells and to deliver those cells into your body so that they can kill your cancer cells. Phase/Status/Sponsor: Unknown phase; COMPLETED; TVAX Biomedical.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Immunophenotyping From Blood of Patients With Malignant Gliomas is being studied. Conditions: Anaplastic Astrocytoma, Glioblastoma Multiforme • Eligibility: Inclusion Criteria: * patients with glioblastoma or anaplastic astrocytoma * legal age * planned chemoradiation and adjuvant chemotherapy (according to Stupp et. al.) Exclusion Criteria: * Fertile patients…. Goal: In this explorative study immunological changes during tumor therapy will be analyzed in patients with malignant glioma. Immunophenotyping before and during therapy is used as analysis method. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Erlangen-Nürnberg Medical School.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma is being studied. Conditions: Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma +5 • Eligibility: Inclusion Criteria: * Patients must have presumed malignant glioma based on clinical and radiologic evaluation (pathologic confirmation of malignant glioma must be made at the time of stereotactic…. Goal: Malignant gliomas have a very poor prognosis with median survival measured in months rather than years. It is a disease in great need of novel therapeutic approaches. Phase/Status/Sponsor: Unknown phase; COMPLETED; Northwestern University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab is being studied. Conditions: Malignant Glioma, Glioblastoma • Eligibility: Inclusion Criteria: 1. Understand and voluntarily sign and date an informed consent document prior to any study related assessments/procedures are conducted. 2. Males and females at least 18…. Goal: This is a Phase 1/2 clinical trial to evaluate a new combination of drugs, marizomib (MRZ) and bevacizumab (BEV; Avastin®), for the treatment of WHO Grade IV malignant glioma. The study population includes subjects who are in first or second relapse and who have not previously received any bevacizumab or other anti-angiogenic agent or proteasome inhibitor for treatment of malignant glioma. Phase/Status/Sponsor: Unknown phase; COMPLETED; Celgene.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety Study of Afatinib for Brain Cancer is being studied. Conditions: Brain Cancer • Eligibility: Inclusion Criteria: * Diagnosis 1. Dose Escalation Cohorts: Histologically confirmed diagnosis of brain cancer: 1. glioblastoma (GBM), 2. anaplastic astrocytoma (AA), 3. anaplastic oligodendroglioma (AO), 4. anaplastic mixed…. Goal: The purpose of this study is to try to determine the maximum safe dose of afatinib that can be administered to people with brain cancer. Other purposes of this study are to: * find out what effects (good and bad) afatinib has; * see how much drug gets into the body by collecting blood and cerebrospinal fluid for use in pharmacokinetic (PK) studies; * learn more about how afatinib might affect the growth of cancer cells; * look at biomarkers (biochemical features that can be used to measure the progress of disease or the effects of a drug). Phase/Status/Sponsor: Unknown phase; COMPLETED; Santosh Kesari.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors is being studied. Conditions: Brain Tumors, Metastatic Disease • Eligibility: INCLUSION CRITERIA: * Adults \>18 years old. * Life expectancy of at least \> 30 weeks. * Must have received a prior course of at least 30 Gy…. Goal: RATIONALE: Donepezil may help lessen confusion and fatigue and improve mood and quality of life in patients who have undergone radiation therapy for brain tumors. It is not yet known whether donepezil is more effective than a placebo in lessening side effects of radiation therapy in patients with brain tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; Wake Forest University Health Sciences.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma is being studied. Conditions: Brain Tumor, Astrocytoma, Astroglioma +2 • Eligibility: * INCLUSION CRITERIA: * Inclusion criteria are same in both Phase I and Phase II parts, except for the number of prior disease relapses * Patients must have…. Goal: Background: Zotiraciclib (TG02) is an investigational drug that penetrates the blood-brain barrier and might treat brain tumors. Temozolomide (TMZ) is a drug used to treat brain tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor is being studied. Conditions: Brain and Central Nervous System Tumors, Radiation Toxicity • Eligibility: DISEASE CHARACTERISTICS: * Diagnosis of primary brain tumor or brain metastases, meeting 1 of the following criteria: * No radiographic evidence of disease * Stable disease, defined as…. Goal: RATIONALE: Donepezil and EGb761 may be effective in improving neurocognitive function (such as thinking, attention, concentration, and memory) and may improve quality of life in patients who have undergone radiation therapy to the brain. PURPOSE: This phase II trial is studying how well donepezil or EGb761 works in improving neurocognitive function in patients who have undergone radiation therapy for primary brain tumor or brain metastases. Phase/Status/Sponsor: Unknown phase; COMPLETED; Wake Forest University Health Sciences.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields is being studied. Conditions: Malignant Glioma • Eligibility: Inclusion Criteria: * Written informed consent prior to beginning specific protocol procedures * Histologically proven World Health Organization (WHO) grade IV malignant glioma * Completed standard-of-care treatment for…. Goal: This purpose of this study is to describe the effect of Tumor Treating Fields (NovoTTF) on quality of life (QOL), including exercise, sleep quality, and mood, in patients with World Health Organization (WHO) Grade IV malignant glioma who have been prescribed and approved to receive Optune™. This is an observational, longitudinal study, meaning that information about QOL will be collected over time while the patient is using the NovoTTF device (for example, Optune™). Phase/Status/Sponsor: Unknown phase; COMPLETED; Duke University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer is being studied. Conditions: Glioblastoma, Malignant Glioma • Eligibility: Inclusion Criteria: * Signed Informed Consent Form * Males and females of age ≥ 18 years or of age ≥ 22 years for those assigned to Optune™ at…. Goal: This study is for newly diagnosed WHO Grade IV malignant glioma patients to determine whether an investigational drug known as marizomib (MRZ) will improve the treatment of newly diagnosed glioblastoma patients by delaying the growth of the cancer, reducing the size of the tumor, and/or improving survival. Marizomib (MRZ) is being added to standard-of-care treatments of radiotherapy (RT), temozolomide (TMZ), and Optune. Phase/Status/Sponsor: Unknown phase; COMPLETED; Celgene.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tested an oral drug called enasidenib (AG-221) in adults with IDH2-mutated, advanced solid tumors (including glioma) or angioimmunoblastic T-cell lymphoma (AITL). - It aimed to learn about safety, how the drug behaves in the body (pharmacokinetics), and whether it shows any clinical activity against the cancer. - The study started with dose escalation to find the maximum tolerated dose (MTD) and a recommended Phase 2 dose, then planned expansion cohorts to further evaluate safety and activity. - Eligibility required adults 18+, confirmed IDH2-mutated disease, and adequate organ function; key exclusions included pregnancy, significant heart problems or QT prolongation risk, active infections, and certain interacting medications.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders is being studied. Conditions: Brain and Central Nervous System Tumors, Metastatic Cancer, Radiation Toxicity • Eligibility: DISEASE CHARACTERISTICS: * Diagnosis of brain tumor or other brain disorder, including, but not limited to, 1 of the following: * Primary brain tumors * Brain metastases *…. Goal: RATIONALE: Learning about the side effects of stereotactic radiosurgery in patients with brain tumors or other brain disorders may help doctors plan treatment and help patients live more comfortably. PURPOSE: This clinical trial is studying the acute side effects in patients who are undergoing stereotactic radiosurgery for brain tumors or other brain disorders. Phase/Status/Sponsor: Unknown phase; COMPLETED; Case Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Glioma Modified Atkins-based Diet in Patients With Glioblastoma is being studied. Conditions: Glioblastoma Multiforme • Eligibility: Inclusion Criteria: 1. Patients must have a clinical and histopathologic diagnosis of GBM, have completed \>80% of prescribed concurrent radiation therapy and adjuvant temozolomide without CTCEA grade 3…. Goal: The primary goal of this study is to assess the feasibility and biologic activity of a modified Atkins-based diet combined with short-term intermittent fasting, a GLioma Atkins-based Diet (GLAD), in patients with central nervous system GBM. Phase/Status/Sponsor: Unknown phase; COMPLETED; Wake Forest University Health Sciences.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Intra-operative Variation in Size of Brain Tumors After Craniotomy is being studied. Conditions: Brain Tumor, Primary • Eligibility: Inclusion Criteria: * All patients above the age of 15 years conferring to Grade I and II of American Society of Anesthesiologist (ASA) physical status classification system, undergoing…. Goal: We planned to evaluate the change in tumor dimensions of intraaxial parenchymal tumors after craniotomy by comparing the tumor size on intraoperative ultrasonography (IOUSG) with pre-operative CECT and CEMRI brain. Phase/Status/Sponsor: Unknown phase; COMPLETED; Sheri Kashmir Institute of Medical Sciences.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Blood and Cheek Cell Samples From Patients With Glioma is being studied. Conditions: Brain and Central Nervous System Tumors • Eligibility: DISEASE CHARACTERISTICS: * Diagnosis of glioma * Meets 1 of the following criteria: * Participant in the Survival study of San Francisco Bay Area Adult Glioma Study (SFBAAGS)…. Goal: RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of California, San Francisco.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Feasibility of Lymphocyte Reinfusion in Newly Diagnosed High Grade Gliomas is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: * • Age≥18 year * New diagnosed high grade glioma * Post-operative treatment with standard RT/TMZ * Karnofsky performance status ≥ 60% * Normal bone marrow…. Goal: This research study is being done to see if lymphocytes can be collected from patients with high grade gliomas before they start standard radiation and chemotherapy. (Lymphocytes are cells that normally circulate in the blood and are an essential part of the immune system). Phase/Status/Sponsor: Unknown phase; COMPLETED; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety of BBB Opening With the SonoCloud is being studied. Conditions: Glioblastoma, Glioma, Brain Tumor • Eligibility: Inclusion criteria: * Age greater than 18 years. * Subjects with recurrent glioma who have failed standard therapy with surgery and/or treatment with radiation and temozolomide. * Patient…. Goal: PURPOSE: The purpose of this study is to determine whether transient opening of the blood-brain barrier by pulsed ultrasound using the SonoCloud implantable ultrasound device is safely tolerated in patients with recurrent glioblastoma immediately before systemic delivery of carboplatin-based chemotherapy. STUDY HYPOTHESIS: The blood-brain barrier can be safely opened using pulsed ultrasound prior to chemotherapy administration in patients with recurrent glioblastoma. Phase/Status/Sponsor: Unknown phase; COMPLETED; Assistance Publique - Hôpitaux de Paris.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors is being studied. Conditions: Glioblastoma or Gliosarcoma • Eligibility: Inclusion Criteria: * Glioblastoma or gliosarcoma in first or second recurrence only * Documented tumor recurrence or progression after failing prior surgical resection, chemotherapy, or radiation * Tumor…. Goal: Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of malignant primary brain tumor in adults and can be resistant to conventional therapies. The purpose of this Phase Ib study is to evaluate how well a recurrent glioblastoma or gliosarcoma tumor responds to one injection of DNX-2401, a genetically modified, conditionally replicative and oncolytic human-derived adenovirus. Phase/Status/Sponsor: Unknown phase; COMPLETED; DNAtrix, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors is being studied. Conditions: Brain and Central Nervous System Tumors, Metastatic Cancer • Eligibility: Inclusion Criteria Patients must be at least 18 years of age. Patients must have either a primary or metastatic brain tumor(s). Patients must be in need of a…. Goal: RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about how this treatment is used by the body. Phase/Status/Sponsor: Unknown phase; COMPLETED; City of Hope Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Temozolomide in Treating Patients With Recurrent High-Grade Glioma is being studied. Conditions: Recurrent Central Nervous System Neoplasm • Eligibility: Inclusion Criteria * Patients with radiographically proven recurrent, intracranial malignant glioma will be eligible for this protocol. * All patients must sign an informed consent * Patients must…. Goal: RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well temozolomide works in treating patients with recurrent high-grade glioma. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of California, San Francisco.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial is being studied. Conditions: Primary Brain Tumor, Glioblastoma, Astrocytoma +3 • Eligibility: Inclusion Criteria: * Primary brain tumor diagnosis (grade I-IV) * \>/=2weeks post-cranial resection (if applicable) * \>/=1 month post-radiation therapy (if applicable) * Able to understand, speak, and…. Goal: This study seeks to investigate an evidence-based, manualized, behavioral health intervention, Cognitive Behavioral Therapy for Insomnia (CBT-I), in individuals with primary brain tumors (PBT) and insomnia. Our project will assess the feasibility and acceptability of recruitment, enrollment, data collection procedures, and retention of individuals with PBT and insomnia in the behavioral health intervention, CBT-I, and investigate the potential benefits of CBT-I within this at-risk and understudied population. Phase/Status/Sponsor: Unknown phase; COMPLETED; Virginia Commonwealth University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy is being studied. Conditions: Glioblastoma, Malignant Glioma • Eligibility: Inclusion Criteria: * Histologically confirmed newly diagnosed grade IV malignant glioma * Planned radiation treatments at Mayo Clinic Arizona or Mayo Clinic Rochester * Willing to sign release…. Goal: This phase II trial studies how well fluorodopa F 18-positron emission tomography/magnetic resonance imaging scan (18F-DOPA-PET/MRI) works in imaging elderly patients with newly diagnosed grade IV malignant glioma or glioblastoma during planning for a short course of proton beam radiation therapy. 18F-DOPA is a chemical tracer that highlights certain cells during imaging. Phase/Status/Sponsor: Unknown phase; COMPLETED; Mayo Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Individual Patient Compassionate Use of GX-I7 is being studied. Conditions: Glioblastoma, High Grade Glioma, Recurrent Glioblastoma +2 • Eligibility: Inclusion Criteria: \- Exclusion Criteria: \-. Goal: Compassionate use of GX-I7 for patients with serious life-threatening illness that have exhausted all available therapies, with no other therapy options. Phase/Status/Sponsor: Unknown phase; NO_LONGER_AVAILABLE; Genexine, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Neoadjuvant Chemoradiation for Resectable Glioblastoma is being studied. Conditions: Glioblastoma, Surgery, High Grade Glioma • Eligibility: Inclusion Criteria: 1. Newly diagnosed GBM with histopathological confirmation. 2. Surgically suitable for subtotal or gross total resection as determined by central review. 3. Karnofsky Performance Status (KPS)\>70…. Goal: Preoperative therapy has not been well studied in resectable glioblastoma. This study attempts to prospectively assess the feasibility and efficacy of preoperative chemo radiation in improving local control, as this is the predominant mode of failure in these patients leading to poor outcomes. Phase/Status/Sponsor: Unknown phase; TERMINATED; Geisinger Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of IK-595 in RAS- or RAF-altered Advanced Tumors is being studied. Conditions: Solid Tumor, Adult, Colorectal Cancer, Pancreatic Cancer +7 • Eligibility: Inclusion Criteria: 1. Patients ≥ 18 years of age. 2. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. 3. Adequate organ function as…. Goal: This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue, administered orally as monotherapy in patients with advanced solid tumors with gene alterations in the RAS- MAPK pathway for whom there are no further treatment options known to confer clinical benefit. Phase/Status/Sponsor: Unknown phase; TERMINATED; Ikena Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM is being studied. Conditions: Glioblastoma Multiforme, Glioblastoma, Glioma +2 • Eligibility: Inclusion Criteria: 1. Patient must agree to testing of GBM tumor promoter methylation status of the MGMT gene and tumor (IDH1) gene mutation status. Tissue may be tested…. Goal: This is an adaptive design, randomized controlled, Phase 3 clinical trial in patients with glioblastoma multiforme (GBM) or gliosarcoma (GS), previously treated with surgery (if appropriate), standard of care chemo-radiation with temozolomide, +/- adjuvant temozolomide, and bevacizumab and now has progressive disease during or after bevacizumab. A total of up to 180 eligible patients with recurrent/progressive GBM or GS will be randomized to receive either the investigational drug (VAL-083) or "Investigator's choice of salvage therapy" as a contemporaneous control, in a 2:1 fashion. Phase/Status/Sponsor: Unknown phase; TERMINATED; DelMar Pharmaceuticals, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas is being studied. Conditions: Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Diffuse Intrinsic Pontine Glioma +3 • Eligibility: Inclusion Criteria: * Patients with newly diagnosed DIPGs, defined as tumors with a pontine epicenter and diffuse involvement of the pons, are eligible without histologic confirmation * Patients…. Goal: This phase I trial studies the side effects and the best dose of adavosertib when given together with local radiation therapy in treating children with newly diagnosed diffuse intrinsic pontine gliomas. Adavosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Social Determinants of Health in Glioblastoma Population is being studied. Conditions: Glioma, Astrocytoma, Oligodendroglioma +3 • Eligibility: Inclusion Criteria: Part 1: * Adults who are 18 years or older * Have a histologically confirmed glioma of any grade (WHO Grade 2-4: astrocytoma, oligodendroglioma, ependymoma, ganglioglioma,…. Goal: The overall aim of this study is to prospectively characterize social health disparities in a cross-sectional cohort of glioma patients with attention to exploring and thematically categorizing the patient-specific and community-level factors. This will be conducted in two parts. Phase/Status/Sponsor: Unknown phase; COMPLETED; Wake Forest University Health Sciences.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Quality of Life and Patient Needs in Advanced High Grade Gliomas is being studied. Conditions: Quality of Life, Brain Tumor, Glioblastoma +2 • Eligibility: Inclusion Criteria: * Age \>18 * Tissue proven diagnosis of a high grade brain tumor * Disease progression by MRI * Therapy resistant tumor to 2nd line chemotherapy…. Goal: There is limited knowledge regarding the quality of life and needs of patients with advanced high grade gliomas, especially during the end of life. By doing this research, we are able to assess caregiver and patient symptoms and needs during the end of life phase of patients with brain tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; Henry Ford Health System.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma is being studied. Conditions: Cytomegalovirus Positive, Glioblastoma, Gliosarcoma +3 • Eligibility: Inclusion Criteria: * Be willing and able to provide written informed consent for the trial * PHASE II DOSE EXPANSION IN RECURRENT GBM UNDERGOING RESECTION: Have histologically confirmed…. Goal: This phase I/II trial studies the side effects and best dose of autologous cytomegalovirus (CMV)-specific cytotoxic T cells when given together with temozolomide and to see how well they work in treating patients with glioblastoma. Autologous CMV-specific cytotoxic T cells may stimulate the immune system to attack specific tumor cells and stop them from growing or kill them. Phase/Status/Sponsor: Unknown phase; COMPLETED; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain is being studied. Conditions: Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Recurrent Brain Neoplasm +2 • Eligibility: Inclusion Criteria: * Patients must have histologically confirmed progressive brain metastases from melanoma or recurrent/progressive malignant glioma (glioblastoma, anaplastic glioma), for which standard curative or palliative measures, with…. Goal: This phase I trial studies the side effects and best dose of STAT3 inhibitor WP1066 in treating patients with malignant glioma that has come back or melanoma that has spread to the brain and is growing, spreading, or getting worse. STAT3 inhibitor WP1066 may stop the growth of tumor cells and modulate the immune system. Phase/Status/Sponsor: Unknown phase; COMPLETED; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma is being studied. Conditions: Glioma, Glioblastoma • Eligibility: Inclusion Criteria: * Suspected first recurrence of a glioblastoma tumor by clinical measures and/or MRI * Age 18-99 years Exclusion Criteria: * Breast feeding/ Pregnancy * Severe psychiatric…. Goal: It was previously shown that 18F-DOPA PET imaging results in intended management changes in 41% of brain tumor patients. However, its impact on patient outcome defined as survival, costs, and/or quality of life has not been demonstrated. Phase/Status/Sponsor: Unknown phase; COMPLETED; Jonsson Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PPX, Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors is being studied. Conditions: Brain Tumor • Eligibility: Inclusion Criteria: * Patients must have histopathologically confirmed, newly diagnosed, glioblastoma multiforme or anaplastic glioma (anaplastic astrocytoma \[AA\], anaplastic oligodendroglioma, and anaplastic oligoastrocytoma) and have not had a…. Goal: The purpose of this study is to determine the antitumor activity of PPX in combination with temozolomide and radiation for patients with newly diagnosed brain tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; howard safran.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme is being studied. Conditions: Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma +4 • Eligibility: Inclusion Criteria: * Histological confirmation of grade 3 or 4 glioma, including astrocytoma, oligodendroglioma, and mixed gliomas, as determined by pre-registration central pathology review (Phase I) * Histological…. Goal: This partially randomized phase I/II trial studies the side effects and the best dose of anti-endoglin monoclonal antibody TRC105 when given together with bevacizumab and to see how well they work in treating patients with glioblastoma multiforme that has come back. Monoclonal antibodies, such as anti-endoglin monoclonal antibody TRC105 and bevacizumab, may find tumor cells and help kill them. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma is being studied. Conditions: Glioblastoma, Gliomas • Eligibility: Inclusion Criteria: * Pathologic evidence of a malignant glioma. * Tissue block or unstained slides must be available for MGMT analysis. * Age 18-70 * KPS \> 50…. Goal: Patients have a newly diagnosed brain tumor called a malignant glioma and participate in the study to see if it is possible to increase the benefit of temozolomide when given after radiation. A recent study showed that patients with newly diagnosed glioblastoma lived longer when treated with both temozolomide and radiotherapy followed by 6 months of temozolomide than patients treated with radiotherapy alone. Phase/Status/Sponsor: Unknown phase; COMPLETED; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System is being studied. Conditions: Central Nervous System Tumor • Eligibility: Inclusion Criteria: * MRI obtained within 30 days of study enrollment documents a measurable lesion consistent with a primary malignant central nervous system tumor for which maximal safe…. Goal: The purpose of this study is to examine the use of a single dose of tozuleristide (24 or 36 mg) and the Canvas imaging system during surgical resection of primary central nervous system (CNS) tumors: Primary gadolinium enhancing (high grade) CNS tumors, primary non-gadolinium enhancing CNS tumors, and primary vestibular schwannoma. The primary objectives of the study is to see how well tozuleristide and the Canvas imaging system during surgical resection will show fluorescence among primary enhancing/high grade CNS tumors; and among the tumors that demonstrate tozuleristide fluorescence, to estimate the true positive rate and true negative rate of fluorescence in tissue biopsies, as well as sensitivity and specificity of tozuleristide fluorescence for distinguishing tumor from non-tumoral tissue. Phase/Status/Sponsor: Unknown phase; COMPLETED; John Yu.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection is being studied. Conditions: Glioblastoma Multiforme, Glioma of Brain • Eligibility: Inclusion Criteria: 1. Prior resection of histologically-diagnosed WHO Grade III or IV glioma. A. Glioma patients who have progressed on or following standard (Stupp regimen) therapy, which included…. Goal: In the proposed trial, patients will be administered ribociclib+everolimus prior to surgical resection of their tumor. Recurrent GBM patients will be randomized into one of the three time-interval cohorts for the first two dose levels. Phase/Status/Sponsor: Unknown phase; COMPLETED; St. Joseph's Hospital and Medical Center, Phoenix.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBM is being studied. Conditions: Glioblastoma, Glioma, Malignant • Eligibility: Inclusion Criteria: * Age ≥ 18 years * Patients newly diagnosed with malignant glioma, IDH wildtype who have undergone surgical resection for their tumor and who are planned…. Goal: The purpose of this study is to better define longitudinal genomic alterations in patients with glioblastoma (GBM), and to determine if plasma circulating tumor DNA (ctDNA) or cell free DNA (cfDNA) is associated with disease recurrence, survival, tumor characteristics, and/or peripheral immunosuppression. Phase/Status/Sponsor: Unknown phase; SUSPENDED; Duke University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma is being studied. Conditions: Malignant Glioma of Brain • Eligibility: Inclusion Criteria: * Histologically proven, newly diagnosed IDH wildtype glioblastoma (GBM) that has a methylated MGMT promoter as assessed by the standardized institutional analysis. * Patients are eligible…. Goal: This is a Phase I study that examines the rate of dose limiting side effects in patients with malignant astrocytoma treated with combination acetazolamide (ACZ) and temozolomide (TMZ). Eligible patients must have histologically proven newly diagnosed, O6-methylguanine-DNA methyltransferase (MGMT) methylated WHO grade III or IV astrocytoma and be planning to undergo treatment with standard adjuvant TMZ (after completing treatment with TMZ and ionizing radiation (IR)). Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Chicago.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ANG1005 in Patients With Recurrent High-Grade Glioma is being studied. Conditions: Glioma, Glioblastoma, Brain Tumor, Recurrent • Eligibility: Inclusion Criteria: 1. ≥ 18 years old 2. GBM and GBM variants, WHO Grade III anaplastic glioma diagnosis confirmed 3. Radiologically confirmed recurrent and bi-dimensionally measurable disease per…. Goal: This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells in patients with high-grade glioma. Another purpose of this study is to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of ANG1005 in patients. Phase/Status/Sponsor: Unknown phase; COMPLETED; Angiochem Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG is being studied. Conditions: Pediatric Brain Tumor, Diffuse Intrinsic Pontine Glioma • Eligibility: Inclusion Criteria: 1. Male or female subjects ≤ 21 years-of-age with the demonstrated ability to swallow capsules whole and who are willing to provide access to previously obtained…. Goal: This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human IL-12. IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the immune system to kill tumor cells and may interfere with blood flow to the tumor. Phase/Status/Sponsor: Unknown phase; TERMINATED; Alaunos Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) is being studied. Conditions: Glioblastoma • Eligibility: * INCLUSION CRITERIA: Pre-Surgery (Step 1) Inclusion: * Magnetic resonance imaging (MRI) findings consistent with a suspected glioblastoma (GBM) or a histologically confirmed newly diagnosed GBM that has…. Goal: Background: Glioblastoma (GBM) refers to a specific kind of brain cancer called glioblastoma. The standard treatment for GBM is radiation plus temozolomide, an oral chemotherapy drug. Phase/Status/Sponsor: Unknown phase; TERMINATED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Feasibility Study of Modified Atkins Ketogenic Diet in the Treatment of Newly Diagnosed Malignant Glioma is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: * Histologically confirmed primary malignant glioma, Grade III or IV * No uncontrolled infection or other active malignancy or chronic systemic immune therapy. * ECOG performance…. Goal: The purpose of this research study is to see if people can produce ketones in their blood with the modified Atkins diet. Modified Atkins diet is a diet that produces ketones in your blood by restricting carbohydrates to \<20 grams per day. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Cincinnati.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Dendritic Cell Vaccine for Patients With Brain Tumors is being studied. Conditions: Glioma, Anaplastic Astrocytoma, Anaplastic Astro-oligodendroglioma +1 • Eligibility: PATIENT ELIGIBILITY Inclusion Criteria 1. Patients with newly diagnosed or recurrent glioma of WHO Grade III or IV {anaplastic astrocytoma (AA), anaplastic astro-oligodendroglioma (AO), or glioblastoma (GBM)} will…. Goal: The main purpose of this study is to evaluate the most effective immunotherapy vaccine components in patients with malignant glioma. Teh investigators previous phase I study (IRB #03-04-053) already confirmed that this vaccine procedure is safe in patients with malignant brain tumors, and with an indication of extended survival in several patients. Phase/Status/Sponsor: Unknown phase; COMPLETED; Jonsson Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Multimodal MR Imaging in Patients With Glioblastoma Treated With Dendritic Cell Therapy is being studied. Conditions: Malignant Gliomas • Eligibility: Inclusion Criteria: \*\*\*\* patients enrolled in the HGG 2003 HGG-IMMUNO 2003 trial Patients, older than 3 and younger than 60 years with relapse of high-grade glioma (anaplastic astrocytoma…. Goal: Malignant gliomas are aggressive tumours with poor prognosis despite the current multimodal treatment. Hence, there is a clear need for new, effective therapies, among which immune therapy has emerged as a promising treatment option. Phase/Status/Sponsor: Unknown phase; COMPLETED; Universitaire Ziekenhuizen KU Leuven.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme is being studied. Conditions: Glioblastoma Multiforme • Eligibility: Inclusion Criteria: * The subject has locally determined histologically confirmed diagnosis of Grade 4 astrocytic tumor. * The subject has received prior standard radiation for Grade 3 or…. Goal: The purpose of this study is to evaluate the objective response rate and 6-month progression-free survival rate of XL184 in subjects with recurrent or progressive glioblastoma multiforme. XL184 is a new chemical entity that inhibits VEGFR2, MET and RET, kinases implicated in tumor formation, growth and migration. Phase/Status/Sponsor: Unknown phase; COMPLETED; Exelixis.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies is being studied. Conditions: Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis, Advanced Cancers • Eligibility: Inclusion Criteria (Escalation and Expansion Phases) Patients must meet the following criteria to be eligible to enroll in the study: 1. Male or female patients ≥18 years of…. Goal: This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of DCC-2618, administered orally (PO), in adult patients with advanced malignancies. The study consists of 2 parts, a dose-escalation phase, and an expansion phase. Phase/Status/Sponsor: Unknown phase; COMPLETED; Deciphera Pharmaceuticals, LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: * Patients or their legal representatives must be able to provide written informed consent. * Histologically confirmed diagnosis of supratentorial GBM (Grade 4 astrocytoma). * Radiographic…. Goal: This is an event driven, adaptive design, a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 3 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent or progressive glioblastoma multiforme (GBM) following treatment with first line therapy consisting of surgery and radiation with or without chemotherapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; Sumitomo Pharma America, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: 1. Patients must be at least 18 years of age 2. Patients must have a Karnofsky performance status \> 60% (i.e. the patient must be able…. Goal: The phase I portion of study is designed to determine the Maximum Tolerated Dose (MTD) of BSI-201 with two clinically relevant dosing regimens of temozolomide (TMZ). Secondary objectives in the phase I trial include determining the PK of BSI-201 in malignant glioma patients and correlating BSI-201 PK with degree of PARP-1 inhibition. Phase/Status/Sponsor: Unknown phase; COMPLETED; Sanofi.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas is being studied. Conditions: Glioblastoma Multiforme, Anaplastic Astrocytoma, Oligoastrocytoma, Mixed +1 • Eligibility: Inclusion Criteria: 1. Must be greater than or equal to 18 years of age. 2. Subjects must have histologically proven GBM, AA, AMO, malignant astrocytoma NOS or gliosarcoma…. Goal: In this study an investigational replication-defective, recombinant adenovirus expressing the interferon-beta gene (BG00001) will be directly injected into tumors, in patients with recurrent Grade III and Grade IV Gliomas, in order to deliver the hIFN-beta gene. The purpose of the study is to evaluate the safety and any harmful effects of injection of BG00001 into brain tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; Biogen.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma is being studied. Conditions: Malignant Glioma, Glioblastoma Multiforme • Eligibility: Inclusion Criteria: * Japanese participants with WHO grade III or IV malignant glioma * 70 or above on Karnofsky Performance Status in Arm A of Phase 1 portion…. Goal: This study seeks to evaluate the tolerability, pharmacokinetics (PK), efficacy, and safety of ABT-414 in Japanese participants with newly diagnosed and recurrent, World Health Organization (WHO) grade III or IV malignant glioma. Phase/Status/Sponsor: Unknown phase; COMPLETED; AbbVie.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma is being studied. Conditions: Glioma, Glioblastoma Multiforme, Astrocytoma • Eligibility: Inclusion Criteria: * Histopathologically confirmed glioblastoma multiforme (with areas of necrosis), malignant astrocytoma and astrocytoma with foci of anaplasia * Karnofsky Performance Score ≥ 60 * Absolute Neutrophil…. Goal: Hyperfractionated radiation therapy (RT) to 72.0 Gy with BCNU will be compared to conventional radiation therapy to 60.0 Gy with BCNU to determine if hyperfractionated RT can improve the median survival time of adults with supratentorial malignant gliomas. Phase/Status/Sponsor: Unknown phase; COMPLETED; Radiation Therapy Oncology Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Improving Ultrasound Images in Brain Tumor Surgery With the Use of Brain Mimicking Fluid is being studied. Conditions: Brain Neoplasms, Glioma • Eligibility: Inclusion Criteria: * A glioblastoma is suspected when there is a solitary brain tumour with ring-like contrast enhancement and oedema with no recent history (last 3 years) of…. Goal: Prognosis in patients with glioblastomas (the most aggressive high-grade glioma) remains unfavourable. Tools for improving brain tumor surgery, in particular for gliomas, are increasing. Phase/Status/Sponsor: Unknown phase; COMPLETED; St. Olavs Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors is being studied. Conditions: Brain Tumor, Recurrent • Eligibility: 1. Age: ≥ 6 months and \< 18 years 2. Disease: Patients with relapsed or refractory brain tumors are eligible. Patients must have had histologic verification of malignancy…. Goal: The goal of this proposal is to evaluate a new Photodynamic Therapy (PDT) modification which could revolutionize the treatment of brain tumors in children and adults. There are currently few cases published involving the use of PDT in infratentorial (in the posterior fossa) brain tumors in general and specifically those occurring in children. Phase/Status/Sponsor: Unknown phase; COMPLETED; Harry T Whelan, MD.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor is being studied. Conditions: Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma +1 • Eligibility: Inclusion Criteria: * Has the subject given written informed consent? * Is the subject between 18 years old and 80 years old inclusive? * Has the subject had…. Goal: This is a multicenter study evaluating the safety and tolerability of Toca 511 administered intravenously to patients with recurrent or progressive Grade III or Grade IV Gliomas who have elected to undergo surgical removal of their tumor. Patients meeting all of the inclusion and none of the exclusion criteria will receive an initial dose of Toca 511 administered as an intravenous, bolus injection, followed approximately 11 days later by an additional dose injected into the walls of the resection cavity at the time of planned tumor resection. Phase/Status/Sponsor: Unknown phase; COMPLETED; Tocagen Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG is being studied. Conditions: High Grade Glioma, BRAF V600E, BRAF V600K +4 • Eligibility: Inclusion Criteria: 1. Patients receiving any other standard or investigational agents are ineligible. 2. Patients with history or current evidence of the following conditions are excluded: neuromuscular disorder…. Goal: The goal of this study is to estimate the efficacy of encorafenib and binimetinib as measured by radiographic response in recurrent high-grade primary brain tumors. Phase/Status/Sponsor: Unknown phase; TERMINATED; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme is being studied. Conditions: Glioblastoma, Glioblastoma Multiforme • Eligibility: Inclusion Criteria: * Age 18 or older * Diagnosis of histologically confirmed glioblastoma (WHO grade IV). Subjects with an original histologic diagnosis of low grade glioma or anaplastic…. Goal: One of Disulfiram antitumor effects suggested in preclinical studies is MGMT (methyl-guanine-methyl-transferase) inhibition. Disulfiram MGMT inhibitory effect is enhanced by addition of Copper. Phase/Status/Sponsor: Unknown phase; TERMINATED; Wake Forest University Health Sciences.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas is being studied. Conditions: Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma +3 • Eligibility: Inclusion criteria 1. Be informed of the nature of the study and have provided written informed consent 2. At least 18 years of age 3. ECOG performance of…. Goal: This is a single-center, open-label, non-randomized, Phase I/IIa study to investigate the safety, tolerability, and antitumor efficacy of AXL1717 (picropodophyllin as active agent formulated in an oral suspension; PPP) in patients with recurrent malignant astrocytomas (glioblastoma, gliosarcoma, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and anaplastic ependymoma). Patients will be treated for up to 5 cycles. Phase/Status/Sponsor: Unknown phase; TERMINATED; Rush University Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.